(Natural News) One of the latest additions to the Trump White House, Moncef Slaoui is slated to head up the president’s “Operation Warp Speed” program for fast-tracked Wuhan coronavirus (COVID-19) vaccines. And as you might expect, the guy loves his pharmaceuticals.
Before being hired as the go-to for developing a pandemic jab, Slaoui was deeply tied to Big Pharma – and probably still is. His most recent seat on the board of Moderna, a Cambridge, Mass.-based biotechnology firm, afforded him lucrative stock options that within days of his appointment increased nearly $2.4 million to $12.4 million.
As it turns out, Moderna had already been working on a vaccine for the Wuhan coronavirus (COVID-19) that was moving through the clinical trial process. And Slaoui decided to sell his shares from it after previously stating that they did not represent a conflict of interest, promising to donate the proceeds to cancer research.
But what many people do not know is that Slaoui’s holding in Moderna was just one of many stocks that he holds as part of a massive pharmaceutical portfolio. Most of these holdings are not public, which means Slaoui is profiting in secret while supposedly representing the American people at the public level.
The kicker, and Slaoui’s way around this, is that he technically was not hired on as a government employee. Unbelievably, Slaoui is merely on “contract,” and receives just $1 for his “service” to the White House. This means that he is not required to disclose his other stock holdings, as well as positions or any other potential conflicts of interest.
This new contract position held by Slaoui also allows him to avoid all conflict-of-interest laws and regulations that executive branch employees would otherwise be required to follow since he is not technically a federal employee.
“Dr. Slaoui, 60, has spent his career developing vaccines and biotechnology businesses, and he has the investments and board seats to prove it,” reports DNYUZ.com.
“He still holds just under $10 million in GlaxoSmithKline stock and remains a partner in Medicxi, a venture capital firm that specializes in investing in biotech concerns, with several companies engaged in the global race to develop treatments or vaccines to stanch the coronavirus pandemic. GSK and Sanofi have become partners in creating a vaccine candidate against the coronavirus.”
Listen below to The Health Ranger Report as Mike Adams, the Health Ranger, gives his take on how he does not believe, despite this appointment, that President Trump is in bed with Big Pharma and its vaccine agenda:
Slaoui’s boss Alex Azar also has deep financial ties to Big Pharma
Slaoui is hardly the first questionable appointment by Trump, as Slaoui’s immediate boss Alex M. Azar II, who currently serves as the secretary of the Department of Health and Human Services (HHS), is similarly a former Big Pharma executive who used to work for Eli Lilly.
Scott Gottlieb, who used to head up the Food and Drug Administration (FDA), was also a Big Pharma top dog who moved in and out of government not once but twice. Gottlieb is now gone, of course, but like Slaoui, he supposedly divested of his competing interests upon first assuming his role at the FDA in 2017.
According to those in the Trump administration who are said to have reviewed Slaoui’s outside affiliations, he does not have any conflicts because his advisory roles apparently were unrelated to research on treatments for the Wuhan coronavirus (COVID-19). In his new White House role, however, Slaoui will be evaluating vaccine candidates and deciding whether or not they should receive federal financial backing.
To keep up with the latest news about the Wuhan coronavirus (COVID-19), be sure to check out Pandemic.news.
Sources for this article include: